Review
Accepted on 05 Dec 2025
Pharmacological Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Non-Small Cell Lung Cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Type at least 3 characters
2,044 articles
Review
Accepted on 05 Dec 2025
The DDR-Immune Fitness Score: A Biomarker for Guiding PARP and Immunotherapy Synergy in Extensive-Stage Small Cell Lung Cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Review
Accepted on 05 Dec 2025
Mitophagy in Gastrointestinal Tumors: Mechanisms and New Targets for Immunotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Case Report
Published on 05 Dec 2025
Case report: TP53 heterogeneous alteration in grade 3 type I gastric NET: a case implicating primary tumor progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1708609
Original Research
Accepted on 03 Dec 2025
Novel mtDNA methylation-associated prognostic signatures in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Accepted on 03 Dec 2025
Downregulation of OPCML Is Associated with Activation of AKT Signaling and Aggressive Phenotypes in Glioblastoma Cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Published on 03 Dec 2025
Mechanistic role of CD82 palmitoylation in augmenting antitumor drug sensitivity via apoptosis regulation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1699420
- 201 views
Correction
Accepted on 02 Dec 2025
Correction: Targeting PDCD4 in cancer and atrial fibrillation: mechanistic insights from integrated multi-omics and single-cell analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Accepted on 02 Dec 2025
MYO19 is Associated with Tumor Progression, Immune Evasion, Ferroptosis-Related Signatures in Lung Squamous Cell Carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Accepted on 02 Dec 2025
NOP56 interacts with Fibrarin to regulate the PI3K/AKT signaling pathway and inhibit apoptosis of hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Systematic Review
Published on 02 Dec 2025
The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1706837
- 574 views
Mini Review
Published on 01 Dec 2025
Layilin: a multifunctional hyaluronan receptor in physiology and pathology
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1721065
- 502 views
Brief Research Report
Published on 01 Dec 2025
TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1689771
- 373 views
Review
Published on 01 Dec 2025
Sleepyhead, deadly awakening: the dynamics of metastatic organotropism, tumor dormancy and therapeutic implications
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1701031
- 463 views
Case Report
Accepted on 29 Nov 2025
Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 118 views
Original Research
Accepted on 28 Nov 2025
Dose-Escalated Icotinib in Frail, Elderly Patients with EGFR-Mutant Lung Adenocarcinoma: Real-World Efficacy and Safety in a High-Risk Cohort
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 315 views